Background and Aims Lack of non-injectable naloxone formulations has impeded widespread take-home provision for
INTRODUCTION
Opioid overdose constitutes a major international public health problem [1] . Overdose deaths from heroin and other opioids can be prevented through timely administration of the antagonist naloxone.
Naloxone was, until recently, licensed only as injection. Regulatory criteria for non-injectable naloxone have been proposed [2] and, in 2015/16, a first naloxone nasal spray (4 mg/0.1 ml) was approved in the United States [3] and Canada [4] , with 44-47% mean bioavailability relative to intramuscular (i.m.) injection [5] .
Some opioid overdoses have insidious onset, while others occur rapidly. Recently, Darke & Duflou [6] analysed the time-course of opiate metabolites post-mortem and concluded that heroin overdose death occurred within 20-30 minutes of injecting in 43% of cases, suggesting that the time window for naloxone administration may be very narrow [7] . Hence, analysis of naloxone pharmacokinetics in the first 20-30 minutes is particularly important.
In this new analysis of previously unpublished data from a 2004 pharmacokinetic study of naloxone nasal spray (which investigated abuse liability of an oral oxycodone/naloxone formulation), we consider the potential of the studied high-concentration intranasal (i.n.) naloxone formulations from the different perspective of overdose reversal, with two aims: to assess (1) their pharmacokinetic properties and (2) naloxone absorption in the clinically relevant period of the first 30 minutes post-administration.
METHODS

Study design
We report data from a pharmacokinetic study with healthy volunteers conducted in 2004 by Purdue Pharma LP (Ardsley, NY, USA). Ethics approval was granted by the Western Institutional Review Board (Olympia, WA, USA). Its key features (eligibility criteria, etc.) are summarized in the Supporting Information, Appendix S1. Participants received naloxone in four dose/route combinations (one per session) in a four-way cross-over Latin-square design. The four naloxone sessions compared 1 mg/ml intravenous (i.v.) reference with 16 mg/ml sublingual (s.l.) administration and two i.n. doses: 8 mg/0.4 ml from 20 mg/ml and 16 mg/0.4 ml from 40 mg/ml solution.
Naloxone hydrochloride 10 mg/10 ml vials for 1 mg/ml i.v. bolus injection were obtained from Bristol-Meyers Squibb (New York, NY, USA). The s.l. dose [16 mg/ ml; prepared from naloxone-hydrochloride powder (Mallinckrodt Pharmaceuticals, St Louis, MO, USA) in 0.9% sodium-chloride solution] was administered by having subjects retain the solution under the tongue for 5 minutes. Intranasal solution was prepared by dissolving naloxone-hydrochloride powder (see above; 11.0 g for 20 mg/ml; 22.0 g for 40 mg/ml solution) in sodium citrate stock solution (9.35 g for 20 mg/ml; 20.9 g for 40 mg/ml) and brought up to 500 ml volume using 0.9% sodium chloride solution. Intranasal solution was atomized using metered dose nasal spray devices (comprising a pump spray assembly threaded onto a small amber glass bottle), with two 0.1 ml aerosol actuations delivered per nostril, for a 0.2 ml total volume per nostril. Subjects were required to remain upright (seated or standing) with the head tilted slightly forward from dosing until 4 hours post-dosing. Pharmacokinetic blood samples were drawn into tubes containing the anti-coagulant K 2 ethylenediamine tetraacetic acid (EDTA). Blood was collected pre-dosing and at minutes 1, 2, 4, 10, 30 and 40 and hours 1, 2, 4, 6, 8, 12, 16 and 24.
Bioanalysis was conducted by Purdue Pharma L.P. Naloxone plasma concentration was determined by a validated liquid extraction method using liquid chromatography-mass spectrometry (LC-MS/MS). The range of quantification was 0.01-1.0 ng/ml. Concentrations below the limit of quantification were set to zero for pharmacokinetic calculations.
Outcome measures for this new analysis
Our interest was the potential of i.n. naloxone for opioid overdose reversal, and consequently we focused on the pharmacokinetics within the first half-hour, examining plasma naloxone sample concentrations from dosing to 30 minutes.
Partial area under the curve (AUC) values were determined for these sampling points using Phoenix WinNonlin version 6.4. AUC values are expressed as h × ng/ml, i.e. hour(s) × nanograms per millilitre, representing naloxone exposure over time.
We also introduced the exploratory parameter t 50% , defined as time from dosing to concentration equal to 50% of maximum plasma concentration (C max ) [8] .
Statistical analysis
Inferential statistics were calculated using SPSS Statistics version 23. Analysis of variance (ANOVA) was conducted to determine differences in naloxone absorption by treatment arm. Following World Health Organization (WHO) guidance [9] , dose-dependent AUC data were logtransformed to allow for normal distribution in the ANOVA. Tukey's honest significant difference (HSD) test was used for post-hoc comparisons, with significance level at P < 0.05.
RESULTS
Study participants and sensitivity analysis
Twelve eligible healthy subjects were entered into the study, which is within the Food and Drug Administration (FDA) recommendation of six to 36 subjects [10] : five males (age 20-41 years, height 165-193 cm, weight 74-106 kg) and seven females (19-48 years, 157-168 cm, 51-83 kg). Subject 12 did not attend the final 8 mg i.n. session and subject 7 failed to attend the 16 mg s.l. and 1 mg i.v. sessions. These three sessions were handled as missing data. The plasma naloxone concentration from subject 3 was clearly anomalous at 20 minutes following i.v. administration, being five to nine times greater than adjacent time-points (10, 30 minutes) with an AUCt-value (26.85 h × ng/ml) four times greater than the group median (6.64 h × ng/ml). We have excluded all i.v. data for this individual. Consequently, values reported below refer to sample sizes of n = 10 (1 mg i.v.), n = 11 (8 mg i.n., 16 mg s.l.) and n = 12 (16 mg i.n.), unless specified otherwise.
Pharmacokinetics
Plasma naloxone concentrations during the first 6 hours are displayed in Fig. 1 (left-hand graph) and with expanded depiction of the first 30 minutes (right-hand graph). Intravenous administration (1 mg) was characterized by rapid uptake and subsequent decline, whereas s.l. administration (16 mg) showed minimal absorption. Both i.n. administrations (8 mg, 16 mg) had similar time profiles, reaching peak concentrations in less than 30 minutes post-dosing (the 12 subjects' individual plasma-concentration curves are provided in the Supporting Information, Appendix S2).
Pharmacokinetic parameters are shown in Table 1 . The two i.n. administrations (8 mg, 16 mg) displayed similar uptake, with rapid median t max of 20 minutes (0.33 h) for both doses; t 50% was 7-8 minutes for both i.n. doses (8 mg i.n.: x̄= 0.12 h; 16 mg i.n.: x̄= 0.13 h), and hence slower than from i.v. administration (4 minutes; x̄= 0.06 h,). C max values following 8 mg i.n. (x̄= 12.83 ng/ml) and 16 mg i.n. (x̄= 18.25 ng/ml) were greater than those following 1 mg i.v. (x̄= 9.64 ng/ml).
C max values following 16 mg s.l. were extremely low (x̄= 0.90 ng/ml).
Bioavailability
Dose-adjusted AUC data (per mg) from i.n. and s.l. administrations were compared against the 1 mg i.v. reference. As comparisons were not possible for missing and excluded sessions (see Study participants and sensitivity analysis), absolute bioavailability was determined for sample sizes of n = 9 (8 mg i.n.) and n = 10 (16 mg i.n., s.l.).
The mean absolute bioavailability (F%) from dosing to last measureable concentration (AUCt) was 2.0% for s.l. naloxone; hence, it was not considered further; i.n. administration had F% of 27.7% (8 mg) and 24.6% (16 mg; see Table 2 ).
Mean bioavailability values for partial AUC at 1, 2, 4, 10, 20 and 30 minutes post-dosing are reported in Table 2 , with a similar increase over time for both i.n. doses (8 mg, 16 mg): > 5% at 4 minutes, ≥ 13% at 10 minutes and ≥ 20% at 20 minutes. ml) were greater than following 1 mg i.v. (x̄= 1.70 h × ng/ ml; see Table 1 ). These AUC 30 values were dose-adjusted, logtransformed and compared in a one-way, between-subjects ANOVA. AUC 30 values differed significantly as a function of naloxone treatment (F (3,40) = 255.11, P < 0.001). Post-hoc tests showed that dose-adjusted, log-transformed AUC 30 was significantly higher with i.v. [x̄= 3.21, standard deviation (SD) = 0.15] versus both i.n. concentrations (8 mg i.n.: x̄= 2.68, SD = 0.19; 16 mg i.n.: x̄= 2.53, SD = 0.18). However, there was no significant difference between both i.n. concentrations (P = 0.230), suggesting that naloxone absorption was proportional to the i.n. dose administered.
Hence, with dose-adjusted AUC 30 values for 8 mg (x̄= 0.52 h × ng/ml per mg) and 16 mg i.n. (x̄= 0.37 h × ng/ml per mg) and 1 mg i.v. (x̄= 1.70 h × ng/ml) (from above observed values), we calculate, for AUC 30 , that the i.n. dose equivalent to 1 mg i.v. would be 3.3 mg i.n. (20 mg/ml formulation) and 4.6 mg i.n. (40 mg/ml).
Safety
No serious adverse events occurred. Side effects reported after naloxone administration included fainting (three cases; one each after 8 mg i.n., 16 mg i.n., 1 mg i.v.), headache (two cases) and gastrointestinal symptoms (five cases). These 10 cases were distributed by treatment as follows: 8 mg i.n. 
DISCUSSION
Recent WHO guidelines [11] recommend that, similar to adrenaline/epinephrine for the treatment of allergic shock [12] , naloxone should be offered to anyone in the community likely to suffer or witness an opioid overdose ('take-home naloxone', THN). However, the lack of licensed non-injectable naloxone formulations until late 2015 (which continues outside North America) has hindered widespread THN [13] [14] [15] [16] [17] . Once non-injectable solutions exist, naloxone may be provided more widely.
Our analysis identifies a promising pharmacokinetic profile for concentrated naloxone nasal spray. In 2008, Dowling et al. [18] reported only 4% absolute bioavailability with a nasal spray adaptation of a commercially available concentration of naloxone (2 mg/ 5 ml), although the authors suggested that the extremely low bioavailability may be a result of excessive volume at the nasal membrane. In sharp contrast we now report that, at much higher concentrations (8 mg/0.4 ml, 16 mg/0.4 ml), there is a mean absolute bioavailability between 25 and 28%. Even though studied originally for different reasons, we conclude that concentrated solutions of naloxone administered as nasal spray have bioavailability adequate for overdose reversal.
We also report that, crucially, half the maximum observed concentration (t 50% ) was reached within 8 minutes and maximum concentration (t max ) within 20 minutes of i.n. administration. This time profile suggests that concentrated naloxone nasal spray may be suitable for the reversal of overdoses from heroin and other shortacting opioids (e.g. fentanyl), where rapid restoration of respiratory function within 30 minutes of opioid use may be essential [6] .
These results are broadly consistent with the recent paper by Krieter et al. [19] , who reported a C max of 10.3 ng/ml for an 8 mg/0.2 ml i.n. dose as well as t max values of 18-30 minutes and bioavailability of 44-54% (relative to intramuscular reference) for 0.1-0.2 ml of 20 mg/ml and 40 mg/ml i.n. formulations. However, the absence of an intramuscular reference in this study means that a direct bioavailability comparison between the studies is not possible.
We did not find a significant difference between the two nasal formulations in their dose-adjusted naloxone absorption (AUC 30 ). This allowed us to estimate an i.n. dose-equivalent that would deliver the same naloxone exposure within 30 minutes as the reference (1 mg/ml i.v. bolus injection). We calculate that a nasal dose of 3.3 mg (at 20 mg/ml) and 4.6 mg (40 mg/ml) will provide, during the clinically critical initial 30-minute period, the same AUC during 30 minutes as 1 mg/ml i.v.
Algorithms exist for injectable naloxone to guide correct initial and repeat dosing [20] but have yet to be developed for i.n. naloxone. The t 50% data suggest that initial i.n. absorption is delayed compared to the i.v. bolus, with i.n. administration taking 7-8 minutes to attain half the peak concentration (versus 4 minutes for i.v.) and i.n. absolute bioavailability only surpassing 10% between 4 and 10 minutes (see Table 2 ). If this finding is robust, then lay responders may need to be advised to wait some minutes before administering a second i.n. dose to avoid the risk of precipitating over-antagonism. Several limitations need to be borne in mind. Some averages were based on low subject numbers (see Table 1 ). There was also variability in the t max values for i.v. administration (median: 4 minutes), due to two outliers at 4 hours. It is unclear if the low s.l. bioavailability (2%) resulted from subjects possibly swallowing the solution. For the nasal route, only a 0.2 ml volume per nostril was tested in this study, meaning that a volume-absorption relationship cannot be determined. Finally, while it is generally assumed that atomization at a droplet size greater than 10 μm increases nasal absorption [21] , the droplet size distribution was not characterized in this study, and its potential impact on nasal deposition cannot be determined.
We should also give consideration to how quickly the nasal spray versus injectable naloxone can be administered, which then needs to be considered alongside pharmacokinetics-derived speed of onset. For example, in a Vancouver ambulance study, differences in time-torecovery comparing i.v. versus subcutaneous (s.c.) naloxone disappeared when the greater time to establish i.v. access was accounted for [22] .
This data analysis focuses on the clinically relevant first 30 minutes, and it also introduces the measure of t 50% . Also, while our findings support good bioavailability in healthy subjects, concentrated naloxone nasal spray has yet to be tested formally in the target population of opioid users.
The emergence of supportive pharmacokinetic data for concentrated i.n. naloxone, along with approval of a first nasal naloxone spray in North America [3, 4] , constitutes a significant advancement for the field, after concerns over off-label use of injectable naloxone-hydrochloride solution as nasal spray sparked a lively debate in early 2016 [8] .
The time-lag between the original study conducted 13 years ago (with its results subsequently archived), and this new analysis warrants concern. This new analysis identifies the potential of concentrated naloxone nasal spray for overdose reversal (hence authorship of this research report is across academia and industry). There has recently been considerable public investment to conduct healthy volunteer studies of nasal naloxone [19] : the field could have progressed faster had there been awareness of the above data. In future, a mechanism is needed to ensure awareness of relevant data by industry and academia.
CONCLUSION
Concentrated naloxone nasal spray appears to be a feasible formulation with adequate speed of onset and acceptable bioavailability in the concentrated form. This appears directly relevant to prevention of opioid overdoses in medical settings and in the community (THN). The above data find concentrated nasal spray solutions (at 20 and 40 mg/ml) to have acceptable bioavailability and plasma levels over the clinically critical first 30 minutes, with moderate uptake from 4 to 10 minutes onwards. Further examination is required (and is in progress) and dosetitration protocols and repeat-dosing guidance will need development, especially for wider distribution to nonmedical individuals (family members, peers, drug-users themselves). We conclude that concentrated naloxone nasal sprays hold real promise, may enable wider THN provision, and can thereby contribute to the prevention of fatalities from heroin/opioid overdose.
Clinical trial registration
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